Alessandro Follador
Friuli, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 27, 2026
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study.
Journal: Journal for immunotherapy of cancer
Published: April 18, 2025
Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN - ALK fusion.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 28, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 29, 2024
Radiation Recall Pneumonitis Anticipates Bilateral Immune-Induced Pneumonitis in Non-Small Cell Lung Cancer.
Journal: Journal of clinical medicine
Published: December 22, 2022
EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience.
Journal: Journal of thoracic disease
Published: June 02, 2022
Immunotherapy in NSCLC Patients with Brain Metastases.
Journal: International journal of molecular sciences
Published: May 15, 2022
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 28, 2022
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Journal: Future oncology (London, England)
Published: January 24, 2022
The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice.
Journal: Critical reviews in oncology/hematology
Published: August 26, 2021
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
Journal: The oncologist
Published: June 24, 2021
Last Updated: 09/26/2026